5 Key Takeaways

• 1

  Thyroid eye disease (TED) affects approximately 50% of patients with Graves disease, predominantly impacting women.

• 2

  Advancements in understanding TED pathophysiology have led to targeted biologic therapies, particularly IGF-1R antagonism.

• 3

  Traditional treatments like corticosteroids provide limited relief and carry significant risks, highlighting the need for new therapies.

• 4

  Teprotumumab, an IGF-1R antagonist, is the first FDA-approved treatment for TED, showing substantial efficacy in reducing proptosis.

• 5

  Clinical trials demonstrated that teprotumumab significantly outperformed placebo in achieving proptosis reduction and improving symptoms.